NET Clinical Trial Opens: Trial to Assess an Improved Approach to PRRT Treatment

We are pleased to announce that a clinical trial, funded in part by the Neuroendocrine Tumor Research Foundation, has received the necessary regulatory approvals and is open to begin accruing patients. In particular, the clinical trial, Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients with Neuroendocrine Tumors from clinicaltrials.gov will enroll patients with carcinoid cancer for both treatment with the radionuclide, Lutetium-177 and imaging with the radionuclide Gallium-68. Wolfgang Weber, MD, PhD and Diane Reidy-Lagunes, MD, Memorial Sloan Kettering Cancer Center (MSKCC), are the lead researchers on this trial.

Specifically, this trial will assess the potential viability of 68 Ga-DOTA-JR11 and 177 Lu-DOTA-JR11 as a pair of diagnostic and therapeutic radiopeptides for neuroendocrine tumor patients. Gallium 68 is a radionuclide that can be used in diagnostic PET scans. Lutetium 177 is a radionuclide often used with somatostatin analogs to form therapeutic radiopeptides. This study will assess the sensitivity of gallium 68 and the safety of lutetium 177 when combined with the somatostatin antagonist, DOTA-JR11. The trial will employ a new approach to PRRT, the goal of which is to increase efficacy with fewer side effects than other PRRT trials of its kind. A total of 20 patients with progressive, metastatic and inoperable tumors will participate in the clinical trial. We expect the trial to accrue patients very rapidly from a list of those referred to MSKCC.

Learn more about the funded research project. For information about the study, including the inclusion and exclusion criteria for eligibility, click here.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest

18
Leave a Reply

12 Comment threads
6 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
12 Comment authors

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  Subscribe  
newest oldest most voted
Notify of
Carolyn S McCall

Carcinoid tumor removed in 2008 colon resection

Ryssemus

When, on what date will the trial start? Timing is critical for me.
Kind regards,
Henk

For inclusion and exclusion criteria for eligibility, please visit https://clinicaltrials.gov/ct2/show/NCT02609737?term=NCT02609737&rank=1.

I have carcinoid cancer in all three lobes of the liver and cannot operate. I have tumor in pelvis that is inoperable 41 millimeters last checked. And also cancer is outside the lung areas. Would I be a candidate for this study? The original tumor was in the colon and got out into the lymph nodes.

For inclusion and exclusion criteria for eligibility, please visit https://clinicaltrials.gov/ct2/show/NCT02609737?term=NCT02609737&rank=1.

Susan Lizotte

I have Dephnec and have had surgery twice to remove a wedge. I am being treated in Boston and I am from Maine. I am interested in this trial.

For inclusion and exclusion criteria for eligibility, please visit https://clinicaltrials.gov/ct2/show/NCT02609737?term=NCT02609737&rank=1.

Anna Maria Vestal

I would like to be considered for the study.

For inclusion and exclusion criteria for eligibility, please visit https://clinicaltrials.gov/ct2/show/NCT02609737?term=NCT02609737&rank=1.

Mickey

Carcinoid of the small bowel metastisized to liver and lung

[…] • A clinical trial, funded in part by the Neuroendocrine Tumor Research Foundation, has received the necessary regulatory approvals and is open to begin accruing patients. In particular, the clinical trial will enroll patients with carcinoid cancer for both treatment with the radionuclide Lutetium-177 and imaging with the radionuclide Gallium-68. Dr. Wolfgang Weber, and Diane Dr. Reidy-Lagunes, Memorial Sloan Kettering Cancer Center, are the lead researchers on this trial. The trial will employ a new approach to PRRT, the goal of which is to increase efficacy with fewer side effects than other PRRT trials of its kind. https://netrf.org/net-clinical-trial-opens-trial-to-assess-an-improved-approach-to-prrt-treatment/ […]

Manny Fernandez

Hello I’m Manny and I learned I had carcinoid cancer of the small intestines, lymph nodes and liver in August 2013. Surgery removed all known cancer in October 2013. I was not being treated by any drugs for about 15 months and learned the cancer return to the liver and lymph nodes Jan 2015. NIH accepted me for the Ga-68 clinical trial and my first check up showed several lymph nodes with cancer and 20-30 on my liver. My next Ga-68 check up is March 2016. I’m very interested in the clinical trial. Contact info: 937-232-6255 or email: bromanfer@yahoo.com.

[…] We are pleased to announce that a clinical trial, funded in part by the Neuroendocrine Tumor Research Foundation, has received the necessary regulatory approvals and is open to begin accruing patients. In particular, the clinical trial, Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients with Neuroendocrine Tumors Read More […]

[…] Another Clinical Trial For Net Patients – We are pleased to announce that a clinical trial, funded in part by the Neuroendocrine Tumor Research Foundation, has received the necessary regulatory approvals and is open to begin accruing patients. In particular, the clinical trial, Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients with Neuroendocrine Tumors from clinicaltrials.gov will enroll patients with carcinoid cancer for both treatment with the radionuclide, Lutetium-177 and imaging with the radionuclide Gallium-68. Wolfgang Weber, MD, PhD and Diane Reidy-Lagunes, MD, Memorial Sloan Kettering Cancer Center (MSKCC), are the lead researchers on this trial. Read… Read more »

fred lorey

I have a procedural question. I elected not to join this trial at this time because I had a fairly successful chemo-embolization in August, but my question is, is this administered as bound to the injection I receive monthly or is this a general chemo through a port lasting a couple hours? what are the side effects? how well does the material reach the targets given this type of administration compared to the monthly buttocks in injection? thanks

Francine

My mum has MANEC mixed adenoneuroendocrine carcinoma NEC … primary area ‘appendix’ stage IV and metastasis at present (seeding over small intestine & tumour in lower spine with no damage to spine bone) diagnosed Oct 14th by Professor Wilson Belfast City Hospital NI. Female aged 48 …would my mother be a candidate?

Tom

My wife has been fighting for months to get some type of approval such as Compassionate Care. After eleven years and countless surgeries, no more cutting is possible. This treatment has been proven to shrink tumors, about the only possibility left for my wife. It seems rather heartless to let people die even though the treatment has been proven to work consistently. Raising three grandchildren on retirement income and Medicare while caring for my wife means that out of pocket in Houston just won’t happen, much less a trip to Switzerland. Why is the health care system so heartless?

Chris

Is your wife still alive?

NET Clinical Trial Opens: Trial to Assess an Improved Approach to PRRT Treatment